Clinical Trials
- Liver, Obesity & Weight Management
Effects of Hepatic Ultrasound on Metabolic Homeostasis
- Ages18 years - 60 years
- GenderBoth
- Liver, Obesity & Weight Management
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
- Ages12 years - 18 years
- GenderBoth
- Liver
A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)
- Ages18 years and older
- GenderBoth
- Liver
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)
- Ages18 years - 75 years
- GenderBoth
- Liver
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)
- Ages18 years - 75 years
- GenderBoth
- Liver
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)
- Ages18 years - 75 years
- GenderBoth
- Liver
Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS)
- Ages18 years - 75 years
- GenderBoth
- Liver
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)
- Ages18 years - 75 years
- GenderBoth
- Liver, HIV/AIDS, Infectious Disease
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
- Ages18 years and older
- GenderBoth
- Diabetes, Blood Disorders, Liver, Immune System
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease